Jaktinib Hydrochloride Tablet

DRUG3 trials

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions

Atopic DermatitisMyelofibrosis

Phase 1

A Safety and Tolerability Study of Jaktinib

RecruitingNCT05279001

Suzhou Zelgen Biopharmaceuticals Co.,LtdMyelofibrosis

Start: 2024-07-01End: 2025-11-30Target: 26Updated: 2024-03-21

Phase 3

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Active, not recruitingNCT05526222

Suzhou Zelgen Biopharmaceuticals Co.,LtdAtopic Dermatitis

Start: 2022-07-14End: 2026-09-30Updated: 2026-01-05

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

RecruitingNCT05676242

Suzhou Zelgen Biopharmaceuticals Co.,LtdAtopic Dermatitis

Start: 2023-01-11End: 2024-12-31Target: 400Updated: 2024-03-06